Skip to search formSkip to main contentSkip to account menu

2-pyrrolino-DOX

Known as: 2-pyrrolinodoxorubicin, 3'-deamino-3'-(2''-pyrroline-1''-yl)doxorubicin trifluoroacetate 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin
As there is no effective systemic therapy for advanced hepatocellular carcinoma (HCC), we investigated the presence of receptors… 
2005
2005
Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin Analogue AN-215
Purpose: To determine whether the cytotoxic analogue of bombesin/gastrin-releasing peptide (GRP) AN-215 can inhibit the in vivo… 
2004
2004
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
PURPOSE The targeted cytotoxic somatostatin analogue AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201) linked to carrier… 
Highly Cited
2002
Highly Cited
2002
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
The resistance of advanced colorectal cancers to therapy is often related to mutations in the p53 tumor suppressor gene. Because… 
2002
2002
Independently of Their p 53 Status Somatostatin Receptor-positive Experimental Colon Cancers Targeted Cytotoxic Somatostatin Analogue AN-238 Inhibits Updated
The resistance of advanced colorectal cancers to therapy is often related to mutations in the p53 tumor suppressor gene. Because… 
Review
2001
Review
2001
Targeted cytotoxic analogs of luteinizing hormone-releasing hormone: a reply.
We read with great interest the Highlight Review by Dr CG rundker entitled 'Cytotoxic luteinizing hormone- releasing hormone… 
Highly Cited
2000
Highly Cited
2000
Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
The effectiveness of chemotherapy targeted to somatostatin (SST) receptors based on cytotoxic SST analogue AN-238, consisting of… 
1999
1999
Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone.
The selectivity of ligands specific for certain cells can be used to preferentially target chemotherapeutic compounds to… 
Review
1999
Review
1999
Analogue AN-238 Cancer and Its Metastases by Cytotoxic Somatostatin Inhibition of PC-3 Human Androgen-independent Prostate
We evaluated whether AN-238, the cytotoxic analogue of somatostatin (SST) consisting of the radical 2-pyrrolinodoxorubicin (AN… 
1998
1998
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin (targeted chemotherapeutic agentsyhybrid…
To create cytotoxic hybrid analogs of soma- tostatin (SST), octapeptides RC-160 (D-Phe-Cys-Tyr-D-Trp- Lys-Val-Cys-Trp-NH2) and RC… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)